The relationship between -C344/T aldosterone synthase (CYP11B2) gene polymorphism, enzyme activity level and increased risk of nonvalvular atrial fibrillation

• Authors: Yatskevich Karsiaryna , Snezhitskiy Viktor , Kurbat Mikhail , Stepuro Tatiana
• Languages of publication: EN

Keywords

EN

atrial fibrillation, -C344/T aldosteronsynthase (CYP11B2) gene polymorphism; aldosterone synthase activity

• Publisher: Stowarzyszenie Przyjaciół Medycyny Rodzinnej i Lekarzy Rodzinnych
• Journal: Family Medicine & Primary Care Review
• Year: 2015
• Issue: 2
• Pages: 136-139

Contributors

author

Yatskevich Karsiaryna

author

Snezhitskiy Viktor

author

Kurbat Mikhail

author

Stepuro Tatiana

References

• Snezhitskiy VA, Pelesa ES, Deshko MS. Atrial fibrillation. The features of cardiac rhythm regulation and blood oxygen transport.LAP Lambert Academic Publishing; 2013: 116.
• Camm AJ, Lip GYH, Atar D, et al., eds. 2012 focused update of ESC Guidelines for the management of atrial fibrillation: an update of the 2010 guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Europace 2012; 14: 1385–1413.
• Foster RH. Recent progress in understanding aldosterone secretion. Gen Pharmacol 1997; 28: 647–651.
• Marney AM, Brown NJ. Aldosterone and endorgan damage. Clin Sci 2007; 113: 267–278.
• Lendeckel U, Dobrev D, Goette A. Aldosterone-receptor antagonism as a potential therapeutic option for atrial fibrillation. Br J Pharmacol 2010; 159: 1581–1583.
• Tsai CT, Chiang FT, Tseng CD, et al., eds. Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. J Am Coll Cardiol 2010; 55: 758–770.
• Goette A, Hoffmanns P, Enayati W, eds. Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation. Am J Cardiol 2001; 88: 906–909.
• Pei DA, Yan YY, Li L, eds. Mineralocorticoid receptor, CYP11B2 mRNA expression, and atrial matrix remodelling in patients with atrial fibrillation. Acta Cardiol 2010; 65: 527–533.
• Lovati E. Genetic polymorphisms of the rennin–angiotensin–aldosterone system in end-stage renal disease. Kidney Int 2001;60: 46–54.
• Barbato A, Russo P, Siani A, eds. Aldosterone synthase gene (CYP11B2) C-344T polymorphism, plasma aldosterone, renin activity and blood pressure in a multi-ethnic population. J Hypertens 2004; 22: 1895–1901.
• Huang M, Gai X, Yang X, et al., eds. Functional polymorphisms in ACE and CYP11B2 genes and atrial fibrillation in patients with hypertensive heart disease. Clin Chem Lab Med 2009; 47: 32–37.
• Amir O, Amir RE, Paz H, et al., eds. Aldosterone synthase gene polymorphism as a determinant of atrial fibrillation in patients with heart failure. Am J Cardiol 2008; 102: 326–329.
• Hilgers KF, Schmidt Bernhard MW. Gene variants of aldosterone synthase and hypertension. J Hypertens 2005; 23(11): 1957––1959.
• White PC, Rainey WE. Editorial: polymorphisms in CYP11B genes and 11-hydroxylase activity. J Clin Endocrinol Metab 2005; 90: 1252–1255.
• . Li YY, Zhou CW, Xu J, et al., eds. C344/T CYP11B2 gene polymorphism and atrial fibrillation: a meta-analysis of 2,758 subjects.PLoS One 2012; 7(11): e50910